Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erdosteine

K L Dechant1, S Noble

  • 1Adis International Limited, Auckland, New Zealand.

Drugs
|December 1, 1996
PubMed
Summary
This summary is machine-generated.

Erdosteine, a mucolytic agent, effectively reduces cough and sputum viscosity in chronic obstructive bronchitis. It also enhances antibiotic efficacy when co-administered for acute exacerbations, demonstrating good tolerability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methods for think-aloud interviews in health-related resource-use research: the PECUNIA RUM instrument.

Expert review of pharmacoeconomics & outcomes research·2023
Same author

The Rise of Supportive Oncology: A Revolution in Cancer Care.

Clinical oncology (Royal College of Radiologists (Great Britain))·2023
Same author

Proper understanding of recurrent stress urinary incontinence treatment in women (PURSUIT): a randomised controlled trial of endoscopic and surgical treatment.

Trials·2022
Same author

COVID-19 confessions: a qualitative exploration of healthcare workers experiences of working with COVID-19.

BMJ open·2020
Same author

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial.

BMC cancer·2020
Same author

Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale.

Thrombosis research·2020
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Background:

  • Erdosteine is a thiol derivative used for chronic obstructive bronchitis.
  • Its active metabolites possess mucolytic and antioxidant properties.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of erdosteine in managing chronic obstructive bronchitis.
  • To assess its effects on cough, sputum, and mucociliary transport.

Main Methods:

  • Clinical studies involving patients with chronic obstructive lung disease.
  • Comparison of erdosteine (300mg BID) with placebo for cough and sputum viscosity.
  • Comparison with ambroxol (30mg BID) for sputum adhesivity.
  • Evaluation of co-administration with amoxicillin in acute exacerbations.

Related Experiment Videos

Main Results:

  • Erdosteine significantly reduced cough frequency/severity and sputum viscosity compared to placebo.
  • It demonstrated superior sputum adhesivity reduction compared to ambroxol.
  • Co-administration with amoxicillin increased antibiotic concentration in sputum, leading to faster symptom improvement.

Conclusions:

  • Erdosteine is an effective and well-tolerated treatment for chronic obstructive bronchitis.
  • It improves expectoration by modulating mucus and enhancing mucociliary transport.
  • Erdosteine enhances antibiotic effectiveness in treating acute infective exacerbations.